Tag: CNS product candidate

July 10, 2017

VistaGen Seeks to Advanced the Development of AV-101

VistaGen Therapeutics appointed Dr. Mark Wallace to its clinical advisory board to advanced the company's non-opioid treatment.
April 27, 2017

VistaGen's AV-101 Featured in Peer-Reviewed Publication

VistaGen Therapeutics announced the publication of a nonclinical study on the effects of AV-101, the company's central nervous system disorder...
March 29, 2017

VistaGen Obtains European Patent For AV-101

VistaGen Therapeutics announced the European Patent Office issued a notice of intention to grant the company's European patent application for...